Ozempic vs Wegovy vs Mounjaro — What’s the Difference?

Why These Three Medications Confuse Everyone

Ozempic, Wegovy, and Mounjaro are three of the most talked-about medications of the last decade — and three of the most misunderstood. Part of the confusion is deliberate: the pharmaceutical industry brands drugs under multiple names to serve different markets. Part of it is genuine complexity: these medications work through similar but meaningfully different mechanisms.

Here is the simplest way to understand the landscape before going deeper:

• Ozempic and Wegovy are the same drug — semaglutide — made by the same company (Novo Nordisk), approved for different conditions at different doses
• Mounjaro is a different drug — tirzepatide, made by Eli Lilly — that works on two hormone pathways instead of one
• Zepbound is Mounjaro under a different name — the same tirzepatide molecule, approved specifically for weight loss in the US

Understanding this structure makes everything else make sense. This guide covers what each medication actually does, what the clinical trials show about weight loss results, the side effect profiles, and how to think about which option suits different situations. For the full nutrition strategy regardless of which medication you use, the GLP-1 Optimization hub covers everything you need to know.

The Three Medications at a Glance

How Each Medication Actually Works

All three medications work by mimicking hormones your body naturally produces after eating. These hormones — called incretins — signal to the brain that you are full, slow the movement of food through your digestive system, and regulate blood glucose. The key difference is which hormones each drug mimics.

Ozempic and Wegovy — the GLP-1 mechanism

Both Ozempic and Wegovy contain semaglutide, which mimics the GLP-1 hormone (glucagon-like peptide-1). According to the Mayo Clinic’s semaglutide prescribing information, this single-hormone approach works through three main pathways:

• Slowing gastric emptying — food stays in the stomach longer, producing extended fullness
• Stimulating insulin release from the pancreas when blood glucose is elevated
• Suppressing glucagon — reducing the liver’s release of stored glucose into the bloodstream

The result is reduced appetite, lower calorie intake, improved blood glucose control, and progressive weight loss. The difference between Ozempic and Wegovy is purely one of dose and approved indication — Wegovy’s 2.4mg dose produces more weight loss than Ozempic’s maximum 2mg dose, but they work through identical mechanisms.

Mounjaro — the dual GLP-1 + GIP mechanism

Mounjaro (tirzepatide) is a genuinely different type of medication. It is the first approved drug to act on two incretin hormone receptors simultaneously — GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). GIP is a hormone that is released from the small intestine after eating and plays a role in fat storage regulation and insulin sensitivity.

The addition of GIP receptor activation is why tirzepatide produces greater weight loss than semaglutide in clinical trials. Both GLP-1 and GIP receptors are found in areas of the brain responsible for appetite regulation — activating both pathways simultaneously produces a stronger and more sustained reduction in appetite than targeting GLP-1 alone.

Research published in the New England Journal of Medicine on the SURMOUNT trials demonstrated that this dual mechanism translates into meaningfully greater weight loss in real clinical populations.

Weight Loss Results — What the Clinical Trials Show

The most important clinical comparison comes from the SURMOUNT-5 trial — a head-to-head study published in the New England Journal of Medicine in 2025 that directly compared tirzepatide and semaglutide in adults with obesity without diabetes over 72 weeks. This is the most rigorous direct comparison available.

An important note on these numbers: clinical trial results are averages across large populations. Individual results vary significantly based on starting weight, diet, activity level, dose, and how consistently the medication is used alongside a structured nutrition plan. The Getting Started with GLP-1 Nutrition guide explains how to structure your eating to maximise results on any of these medications.

Full Comparison — Ozempic vs Wegovy vs Mounjaro

Side Effects — How They Compare

All three medications share a similar side effect profile because they all slow gastric emptying — the mechanism that makes food stay in the stomach longer. The most common side effects are gastrointestinal and typically appear when doses are first started or increased, then improve over time as the body adjusts.

One important comparison: the SURPASS-2 clinical trial found tirzepatide caused slightly less nausea than semaglutide — possibly because the GIP component has a counteracting effect on some gastrointestinal symptoms. However, the difference was modest and should not be a primary decision factor.

Ozempic, Wegovy, or Mounjaro — How to Think About the Choice

This is ultimately a decision that belongs between you and your healthcare provider — they will consider your full medical history, existing conditions, current medications, and insurance coverage. But these frameworks help you understand the typical considerations involved.

One critical point that is often overlooked: stopping any of these medications typically leads to significant weight regain. Research consistently shows that more than 80% of weight lost on GLP-1 medications returns within two years of stopping treatment. This means the decision to start is a long-term commitment — and the nutritional habits built during treatment are what determine whether results can be maintained.

Why Nutrition Matters Regardless of Which Medication You Choose

The clinical trial weight loss numbers — 15% on Wegovy, 20% on Mounjaro — are averages from people who were also counselled on diet and exercise as part of the trial protocol. Real-world results vary significantly based on how well nutrition is structured during treatment.

The three most important nutritional priorities on any GLP-1 medication are:

1. Protein first at every meal — aim for 0.7–1.0g per pound of body weight daily. This is non-negotiable for protecting muscle during rapid weight loss.
2. Eat on a schedule, not on hunger — GLP-1 medications suppress hunger signals so effectively that most users forget to eat. Planned meals at fixed times prevent the under-eating that causes most side effects.
3. Stay above 1,200 calories — dropping below this threshold accelerates metabolic adaptation and muscle loss without producing additional fat loss.

The GLP-1 Optimization hub contains every guide you need to structure nutrition correctly on any of these medications — from protein targets and meal planning to managing specific side effects.

Summary — Ozempic vs Wegovy vs Mounjaro

• Ozempic and Wegovy are the same drug (semaglutide) at different doses for different approved uses — diabetes vs weight loss
• Mounjaro is a different drug (tirzepatide) that activates two hunger-suppressing hormone pathways instead of one
• Weight loss results: Mounjaro produces the highest average weight loss (~20%) followed by Wegovy standard dose (~15%) and Ozempic (~10–15%)
• The SURMOUNT-5 trial — the most rigorous head-to-head comparison — showed tirzepatide produced 47% more relative weight loss than semaglutide over 72 weeks
• Side effects are similar across all three — nausea, fatigue, constipation, and hair loss are primarily nutritional problems, not medication problems
• The right choice depends on your medical history, primary health goal, insurance coverage, and tolerance — always discuss with a healthcare provider
• Nutrition matters regardless of which medication you use — structured protein, hydration, and calorie targets determine the quality of weight loss

Common Questions Answered

Research & References